ALERT Communities Act

Bill Number

H.R. 1561

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2026-06-25: Forwarded by Subcommittee to Full Committee by Voice Vote.

Last Updated

2026-06-27T08:06:49Z

AI-Generated Summary

Purpose

The ALERT Communities Act (H.R. 1561) aims to combat the opioid crisis by promoting the development, use, and accessibility of test strips that detect dangerous substances like fentanyl and xylazine in drugs or human samples. It focuses on research, training, and funding to reduce overdoses and improve public health responses.

Key Provisions

• Short Title: The bill is officially named the "Advancing Lifesaving Efforts with Rapid Test strips for Communities Act" or "ALERT Communities Act."
• First Responder Training (Section 2): Amends the Public Health Service Act to require training programs for first responders (e.g., paramedics, police) and community members on how to carry and distribute fentanyl or xylazine test strips. This builds on existing grant programs for substance use disorder prevention.
• Research and Marketing Frameworks (Section 3): Directs the Secretary of Health and Human Services (HHS), in consultation with the National Institutes of Health (NIH), Office of National Drug Control Policy (ONDCP), Food and Drug Administration (FDA), and Drug Enforcement Administration (DEA), to create public guidelines for developing, testing, and marketing test strip technology. These frameworks include:
• Standards for manufacturers to create and evaluate new test strips.
• Emphasis on tools for clinical settings to support quick on-site decisions.
• Information on regulatory approval processes for these devices.
• Study on Test Strip Interventions (Section 4): Requires HHS to conduct a study evaluating how access to drug-checking tools like test strips affects overdose rates, overdose deaths, and participation in substance use disorder treatment. A report on findings must be submitted to Congress within two years of enactment.
• Definition (Section 5): Defines a "test strip" as a single-use, rapid diagnostic tool that detects harmful substances (e.g., fentanyl, xylazine, or other synthetic opioids) in drugs or human samples, which could increase health risks like illness or death.

Significant Changes to Existing Law

• The primary change is an amendment to Section 546(c) of the Public Health Service Act (42 U.S.C. 290ee-1(c)), which expands federal grant programs for substance use disorder activities. It adds a new requirement (paragraph 5) for training on test strips, allowing grant funds to support their distribution and use. This integrates test strips into existing public health infrastructure without creating new standalone programs.

Potential Impacts

• Government Agencies: HHS, NIH, ONDCP, FDA, and DEA will need to collaborate on research frameworks and studies, potentially increasing workload and resource allocation for drug detection technologies. Grant programs under the Public Health Service Act can now explicitly fund test strips, streamlining federal support for harm reduction.
• Citizens: Enhances access to affordable, easy-to-use tools for detecting contaminated drugs, which could lower overdose risks for individuals with substance use disorders, their communities, and first responders. The study may inform future policies to boost treatment engagement.
• International Relations: Minimal direct impact, as the bill focuses on domestic public health and research; however, it could indirectly support U.S. efforts in global opioid control by advancing detection technologies.

Main Stakeholders Affected

• First Responders and Community Organizations: Required to receive training and resources for test strip use, improving emergency responses.
• Individuals with Substance Use Disorders: Benefit from increased access to harm reduction tools, potentially reducing overdose incidents.
• Manufacturers and Researchers: Gain clear guidelines and pathways for developing and approving new test strip technologies.
• Federal Agencies (HHS, NIH, ONDCP, FDA, DEA): Tasked with leading research, studies, and framework development.
• Congress and Policymakers: Receive study reports to guide future legislation on drug policy.

Notable Legal, Constitutional, or Political Implications

• Legal: Authorizes use of existing grants for test strips without new funding, avoiding budgetary conflicts. It promotes FDA oversight for device approvals, ensuring safety and efficacy while clarifying regulatory paths for innovation. No challenges to existing drug laws; instead, it supports harm reduction as a public health strategy.
• Constitutional: Aligns with Congress's authority under the Commerce Clause to regulate public health and interstate drug issues; no apparent free speech, privacy, or due process concerns.
• Political: Bipartisan introduction (by Reps. Crockett and Gooden) highlights cross-party focus on the opioid epidemic. It emphasizes evidence-based interventions, potentially influencing broader debates on drug policy by prioritizing prevention over enforcement.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Crockett, Jasmine [D-TX-30]

Cosponsors (1)

Rep. Gooden, Lance [R-TX-5]

Recent Actions

• 2026-06-25: Forwarded by Subcommittee to Full Committee by Voice Vote.
• 2026-06-25: Subcommittee Consideration and Mark-up Session Held
• 2025-02-25: Referred to the Subcommittee on Health.
• 2025-02-25: Referred to the House Committee on Energy and Commerce.
• 2025-02-25: Introduced in House
• 2025-02-25: Introduced in House

Bill Versions

• Advancing Lifesaving Efforts with Rapid Test strips for Communities Act — issued 2025-02-25 — PDF (3 pages)